Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
2.

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G.

EBioMedicine. 2019 Feb;40:290-304. doi: 10.1016/j.ebiom.2018.11.045. Epub 2019 Jan 14.

3.

The polyaromatic hydrocarbon β-naphthoflavone alters binding of YY1, Sp1, and Sp3 transcription factors to the Dp71 promoter in hepatic cells.

Becerril-Esquivel C, Peñuelas-Urquides K, Blancas-Sánchez E, Zapata-Benavides P, Silva-Ramírez B, Chávez-Reyes A, Castorena-Torres F, Cisneros B, Bermúdez de León M.

Mol Med Rep. 2018 Apr;17(4):6150-6155. doi: 10.3892/mmr.2018.8626. Epub 2018 Feb 21.

PMID:
29484433
4.

Organotin Dyes Bearing Anionic Boron Clusters as Cell-Staining Fluorescent Probes.

Muñoz-Flores BM, Cabrera-González J, Viñas C, Chávez-Reyes A, Dias HVR, Jiménez-Pérez VM, Núñez R.

Chemistry. 2018 Apr 11;24(21):5601-5612. doi: 10.1002/chem.201705804. Epub 2018 Mar 8.

PMID:
29338104
5.

Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer.

Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G.

Cell Discov. 2017 Sep 12;3:17029. doi: 10.1038/celldisc.2017.29. eCollection 2017.

6.

Synergistic Antimicrobial Effects of Silver/Transition-metal Combinatorial Treatments.

Garza-Cervantes JA, Chávez-Reyes A, Castillo EC, García-Rivas G, Antonio Ortega-Rivera O, Salinas E, Ortiz-Martínez M, Gómez-Flores SL, Peña-Martínez JA, Pepi-Molina A, Treviño-González MT, Zarate X, Elena Cantú-Cárdenas M, Enrique Escarcega-Gonzalez C, Morones-Ramírez JR.

Sci Rep. 2017 Apr 18;7(1):903. doi: 10.1038/s41598-017-01017-7.

7.

Exosomes: From Garbage Bins to Promising Therapeutic Targets.

H Rashed M, Bayraktar E, K Helal G, Abd-Ellah MF, Amero P, Chavez-Reyes A, Rodriguez-Aguayo C.

Int J Mol Sci. 2017 Mar 2;18(3). pii: E538. doi: 10.3390/ijms18030538. Review.

8.

Therapeutic silencing of HPV 16 E7 by systemic administration of siRNA-neutral DOPC nanoliposome in a murine cervical cancer model with obesity.

Chapoy-Villanueva H, Martinez-Carlin I, Lopez-Berestein G, Chavez-Reyes A.

J BUON. 2015 Nov-Dec;20(6):1471-9.

9.

The influence of non polar and polar molecules in mouse motile cells membranes and pure lipid bilayers.

Sierra-Valdez FJ, Forero-Quintero LS, Zapata-Morin PA, Costas M, Chavez-Reyes A, Ruiz-Suárez JC.

PLoS One. 2013;8(4):e59364. doi: 10.1371/journal.pone.0059364. Epub 2013 Apr 2.

10.

Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.

Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G.

Clin Cancer Res. 2013 Apr 1;19(7):1806-15. doi: 10.1158/1078-0432.CCR-12-2764. Epub 2013 Feb 5.

11.

Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G.

Clin Cancer Res. 2011 Jun 1;17(11):3716-26. doi: 10.1158/1078-0432.CCR-11-0233. Epub 2011 Apr 21.

12.

c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.

Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G.

Clin Cancer Res. 2010 Jan 1;16(1):184-94. doi: 10.1158/1078-0432.CCR-09-1180. Epub 2009 Dec 22.

13.

Murine interferon-gamma inducible protein-10 (IP-10) secreted by Lactococcus lactis chemo-attracts human CD3+ lymphocytes.

Villatoro-Hernandez J, Arce-Mendoza AY, Rosas-Taraco AG, Esparza-González SC, Guzmán-López S, Elizondo-Omaña RE, Chávez-Reyes A, Saucedo-Cárdenas O, de Oca Luna RM.

Biotechnol Lett. 2009 Nov;31(11):1795-800. doi: 10.1007/s10529-009-0081-7. Epub 2009 Jul 18.

PMID:
19618273
14.

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2006 Aug 15;12(16):4916-24. Erratum in: Clin Cancer Res. 2019 May 15;25(10):3194.

15.

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK.

Cancer Res. 2005 Aug 1;65(15):6910-8.

17.

Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice.

Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G.

Nat Genet. 2004 Jan;36(1):63-8. Epub 2003 Dec 21.

18.

Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets.

Chavez-Reyes A, Parant JM, Amelse LL, de Oca Luna RM, Korsmeyer SJ, Lozano G.

Cancer Res. 2003 Dec 15;63(24):8664-9.

19.

Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.

Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G.

Nat Genet. 2001 Sep;29(1):92-5.

PMID:
11528400
20.

Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice.

McDonnell TJ, Montes de Oca Luna R, Cho S, Amelse LL, Chavez-Reyes A, Lozano G.

J Pathol. 1999 Jul;188(3):322-8.

PMID:
10419603
21.

Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality.

Montes de Oca Luna R, Amelse LL, Chavez-Reyes A, Evans SC, Brugarolas J, Jacks T, Lozano G.

Nat Genet. 1997 Aug;16(4):336-7. No abstract available.

PMID:
9241268

Supplemental Content

Loading ...
Support Center